medigraphic.com
Órgano Oficial del Instituto de Ciencias de la Salud, Hospital Escuela y Facultad de Medicina-Xalapa

2015, Number 2

<< Back Next >>

Rev Med UV 2015; 15 (2)

Clinical components of Metabolic Syndrome

Bolado GVE, Rivera BMR, Soto OMCV, Blasco LG, Romero VLC

Language: Spanish
References: 66
Page: 67-89
PDF size: 875.36 Kb.


ABSTRACT

There is enough evidence about the association of raised fasting glucose, dyslipidemia, insulin action, raised blood pressure and central obesity. This association has become known as the metabolic syndrome; it appears in persons with a wide genetic predisposition, phenotype variation and it is highly conditioned by lifestyle risk factors. The metabolic syndrome can involve a broad range of complications, because it is not a simple disease, but a group of health problems caused by combination of genetic factors and sedentary lifestyles, with a high calorie diet, which stimulate abdominal obesity and promote insulin resistance development. Therefore, metabolic syndrome and their components are associated with a high incidence of cardiovascular disease. The metabolic syndrome provides the background information that health professionals need in the clinical evaluation of their patients. For these reasons, the aim of this publication was to review information as current as possible, from scientific medical journals allocated to meet, prevent and treat the metabolic syndrome.


REFERENCES

  1. Aguilar-Salinas C y col. El síndrome metabólico: un concepto en evolución. Gac Méd Méx 2004;140(2):S41-S48.

  2. Lizarzaburu Robles JC. Síndrome metabólico: concepto y aplicación práctica. An Facmed [online]. 2013 vol.74, n.4 [citado 2014-07-13], pp. 315-320. Disponible en:. ISSN 1025-5583.

  3. Rosas Guzmán J y col. Consenso Latinoamericano de la Asociación Latinoamericana de Diabetes ALAD 2010 VOL. XVIII - No 1.

  4. Gutiérrez JP y col. Encuesta Nacional de Salud y Nutrición. (ENSANUT) Resultados Nacionales. Cuernavaca, México: Instituto Nacional de Salud Pública; 2012 (MX).

  5. Oliver AE, Alcorta GM. Prevalencia y factores de riesgo de hipertensión arterial en escolares mexicanos: caso Sabinas Hidalgo. Salud Pública de México 2009; 55(1):14-18.

  6. Barón FP, Márquez E. Diabetes Mellitus tipo 2 en niños y adolescentes. Medicina Interna de México2010; 26(1):36-47.

  7. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539-53.

  8. Balkau B, Charles MA Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16:442-43.

  9. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421.

  10. Alberti KGMM y col. Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640-5.

  11. Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome: 25–26 August 2002, Washington, DC. Diabetes Care 2003; 26:1297-1303.

  12. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome–a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23:469-80.

  13. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 2005; 366:1059 –1062.

  14. Grundy SM, Cleeman JI, Daniels SR, Donato KA y col. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-52.

  15. Pineda CA. Revista del Departamento de Medicina Familiar, Facultad de Salud, Universidad del Valle y Universidad Santiago de Cali, Cali, Colombia 2008; 39:96-106.

  16. Grima A, León M, Ordóñez B. El Síndrome Metabólico como factor de riesgo cardiovascular. Revista Española de Cardiología 2005; 5:16-20.

  17. Del Río Ligorit A y col. Temas de actualidad en cardiología: El síndrome metabólico. Revista Española de Cardiología 2005; 5:13-21.

  18. Gómez I, Gonzáles JR. Dislipemia diabética, síndrome metabólico y riesgo cardiovascular. Revista Española de Cardiología 2006; 3:13-23.

  19. Ascaso J, y col. Dislipemia del síndrome metabólico. Documento sumario del Foro-HDL. Clínica e Investigación en Arterioesclerosis 2007; 19(5):252-263.

  20. Lahoz C, Mostaza J. La ateroesclerosis como enfermedad sistémica. Revista Española de Cardiología 2007; 60(2):184-195.

  21. Shibata N, Glass CK. Macrophages, oxysterols and atherosclerosis. Circ J 2010; 74(10):2045-51.

  22. Badimón JJ, Ibáñez B. Incremento de las HDL como arma terapéutica en la aterotrombosis. Revista Española de Cardiología 2010; 63(3):323-333.

  23. Cordero A, Moreno J, Alegría E. Hipertensión arterial y síndrome metabólico. Revista española de Cardiología 2005; 5:38-45.

  24. Laclaustra M, Bergua C, Pascual I, Casasnovas J. Síndrome metabólico. Concepto y fisiopatología. Revista Española de Cardiología 2005 Vol. 5 3D-10D.

  25. García E y col. La obesidad y el síndrome metabólico como problema de salud pública. Una reflexión. Salud Púb Méx 2008; 50(6):530-545.

  26. Biesalski HK, Grimm P, Nowitzki S. Nutrición médica. Madrid: Médica Panamericana 2007.

  27. Mataix J, Salas J. Obesidad. En Mataix J. Tratado de nutrición y alimentación 2009; (Vol. II). España: OCEANO/ergon.

  28. Marcos B y col. Obesidad, inflamación e insulino-resistencia: papel de los ligandos del receptor gp 130. Anales del Sistema Sanitario de Navarra 2008; XXXI (2):113-121.

  29. González A y col. Factores de riesgo cardiovascular asociados a obesidad abdominal en adultos aparentemente sanos. Rev. Med del Instituto Nacional del Seguro Social 2008; 56(3):273-279.

  30. Yamoka K, Tango T. Effects of lifestyle modification on metabolic syndrome: a systematic review a meta- analysis. BMC Med 2012; 10:138.

  31. Matía-Martín P, Lecumberri-Pascual E, Calle-Pascual A. Nutrición y síndrome metabólico. Rev. Esp Salud Pública 2007; 81:489-505.

  32. Panagiotakos DB, Pitsavos C, Skoumas Y, Stefanadis C. The Association between food patterns and the metabolic syndrome using principal components analysis: the ATTICA study. J Am Diet Assoc 2007; 107(6):679-987.

  33. Norma Oficial Mexicana NOM-043-SSA2-2012 Servicios Básicos de Salud. Promoción y educación para la salud en materia alimentaria. Criterios para brindar orientación. México, 2012.

  34. Organización Mundial de la Salud. Dieta, nutrición y prevención de enfermedades crónicas. Informe de una consulta mixta de expertos OMS/FAO. Serie de Informes Técnicos, Nº 916. Ginebra, 2003.

  35. Ebrahimof S, Mirmiran P. Nutritional Approaches for Prevention and Treatment of Metabolic Syndrome in Adults. Journal Parmedical Sciences (JPS) 2013; 4:123-134.

  36. Leão LS, de Moraes MM, de Carvalho GX. Koifman RJ. Nutritional Interventions in metabolic syndrome: a systematic review. Arquivos brasileiros de Cardiologia 2011; 97(3):260-5.

  37. Lichtenstein AH y col. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006; 114(1):82-96.

  38. Willett WC. Is dietary fat a major determinant of body fat? Am J Clin Nutr 1998; 67(3 Suppl):556S-62S.

  39. Zhu S, St-Onge MP, Heshka S, Heymsfield SB. Lifestyle behaviors associated with lower risk of having the metabolic syndrome. Metabolism 2004; 53(11):1503-11.

  40. Foster GD y col. A randomized trial of a low-carbohydrate diet for obesity. New Engl J Med 2003; 348(21):2082-90.

  41. Abete I y col. Obesity and the metabolic syndrome: role of different dietary macronutrient distribution patterns and specific nutritional components on weight loss and maintenance. Nutrition Rev 2010; 68(4):214-31.

  42. TeMorenga LA y col. Comparison of high protein and high fiber weight-loss diets in women with risk factors for the metabolic syndrome: a randomized trial. Nutrition J 2011; 10:40.

  43. Angela M Zivkovic, J Bruce German, Arun J Sanyal. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. 2007 American Society for Clinical Nutrition. Am J Clin Nutr 2007; 86(2):285-300.

  44. Oh EG, Bang SY, y col. Effects of a 6-month lifestyle modification intervention on the cardiometabolic risk factors and health-related qualities of life in women with metabolic syndrome. Metabolism 2010; 59(7):1035-43.

  45. Yamaoka K, Tango T. Effects of lifestyle modification on metabolic syndrome: a systematic review and meta-analysis. BMC Med 2012; 10:138.

  46. Appel L, Brands M, Daniels S, Karanja N, Elmer P, Sacks F, Dietary Approaches to Prevent and Treat Hypertension. A Scientific Statement from the American Heart Association. Hypertension 2006; 47:296-308.

  47. Azadbakht L y col. Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. Diabetes Care 2005; 28(12):2823-31.

  48. Hinderliter AL y col. The DASH diet and insulin sensitivity. Current hypertension reports 2011; 13(1):67-73.

  49. Trichopoulou A, Lagiou P. Healthy traditional Mediterranean diet: an expression of culture, history, and lifestyle. Nutrition Rev 1997; 55(11):383-9.

  50. Esposito K y col. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004; 292(12):1440-6.

  51. Pérez-Jiménez F y col. International conference on the healthy effect of virgin olive oil. Eur J Clin Inv 2005;35(7):421-4.

  52. Kolomvotsou AI y col. Adherence to Mediterranean diet and close dietetic supervision increase total dietary antioxidant intake and plasma antioxidant capacity in subjects with abdominal obesity. Eur J Nutr 2013;52(1):37-48.

  53. King DE, Mainous AG 3rd, Geesey ME. Turning back the clock: adopting a healthy lifestyle in middle age. Am J Med 2007;120(7):598-603.

  54. Ekelund U, y col. Physical activity energy expenditure predicts progression toward the metabolic syndrome independently of aerobic fitness in middle-aged healthy Caucasians: the Medical Research Council Ely Study. Diabetes Care 2005;28:1195–1200.

  55. Cornier MA, y col. The metabolic syndrome. Endocr Rev 2008; 29(7):777-822.

  56. Norma Oficial Mexicana NOM-008-SSA3-2010, Para el tratamiento integral del sobrepeso y la obesidad. México, D.F., 2010.

  57. Khaodhiar L, Cummings S, Apovian CM. Treating diabetes and prediabetes by focusing on obesity management. Curr Diab Rep 2009;9(5):348-54.

  58. Shyh G, Cheng-Lai A. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia). Cardiol Rev 2014;22(1):43-50.

  59. Goldberg RB, Mather K. Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program. Arterioscler Thromb Vasc Biol 2012;32(9):2077-90.

  60. Orchard TJ y col. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program Randomized Trial. Ann Intern Med 2005;142:611-19.

  61. Holman RR y col. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.

  62. Grundy SM y col. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.

  63. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.

  64. Israili ZH y col. Metabolic syndrome: treatment of hypertensive patients. Am J Ther 2007;14:386- 402.

  65. Cao Z, Cooper ME. Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes. Acta Diabetol 2012;49(4):243-54.

  66. Kwok CS y col. Bariatric surgery and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis. Int J Cardiol 2014;173(1):20-8.




2020     |     www.medigraphic.com